TSLP and asthma: Recently completed clinical studies include the followings: the trial NCT02698501 (UPSTREAM) to determine whether anti-TSLP decreases airway hyperresponsiveness in asthmatic patients already on daily treatment with ICS; the trial NCT03406078 (SOURCE) to evaluate the oral corticosteroid-sparing potential of tezepelumab in patients with oral corticosteroid-dependent asthma; the trial NCT04048343 (NOZOMI) to assess safety of tezepelumab in Japanese adults and adolescents with inadequately controlled severe asthma [40,45,47].